Biomimesys
Retrospective HCS Pharma 2022
We are glad starting a new Year! But nothing better than assessing what happened along the last one to glance back at the road traveled so far… and looking forward to what’s next!
Biomimesys
Presentation of BIOMIMESYS technology, the first organ-specific in vitro ECM, to develop innovative and predictive 3D cellular models for drug discovery – Academia Sinica, the 1st of November 2022
BIOMIMESYS® is a patented 3D matrix reproducing the physicochemical properties of the extracellular matrix (ECM), different from classical hydrogels used for 3D cell culture. It is composed of native ECM components: Hyaluronic Acid (HA) combined with collagens, adhesion peptides… in the form of a unique hydroscaffold, i.e. exhibiting a dual Read more…
Biomimesys
One month-business trip in Asia (Japan, Singapore, Taiwan)
In order to make known BIOMIMESYS technology, Grégory and Nathalie were in Asia in October during one month. The first step was in Japan. We have worked with our partners from AS ONE and JVC Kenwood. We had the opportunity to visit them in AS ONE office in order to Read more…
News
Feedback from FIE in Paris last week
We were glad to participate in FIE (Food Ingredients Europe) fair, which took place from the 6th to the 8th of December in Paris (as a new place for the fair France). Elodie attended it as a visitor, allowing us to meet again our usual partners and to meet future Read more…
Biomimesys
Meet us in OncoLille Days 2022 where we present a poster about matricial tumoral microenvironment in 3D in vitro models
We are pleased to participate in the first OncoLille Days congress from November 2th to 4th, 2022. Inaugurated on October 12th, 2022, OncoLille Institute aims at developing an interdisciplinary research in oncology, including biology, physics, microtechnologies, chemistry, mathematics, bioinformatics, statisitcs, health technologies and social and human sciences. HCS Pharma collaborates Read more…
News
HCS Pharma is growing!
In October the expansion works started in HCS Pharma. The objective is to double the lab and office surface in the same building as our current premises, in the aim to expand BIOMIMESYS® production line to meet the growing demand while guaranteeing the quality of the products. These works will Read more…
Biomimesys
Welcome to Gaspard in HCS Pharma
We are glad to announce the arrival of Gaspard in our team! Gaspard Delpouve obtained his Diploma of Advanced Technician in Biotechnologies in Lille in 2018, and in 2019 he passed a Bachelor’s degree in health biotechnologies at the University of Nantes. During his studies he completed several internships in Read more…
Biomimesys
HCS Pharma will attend RDV Carnot and will pitch there
Dear all, please feel free to contact Elodie who will be in RDV Carnot event in Paris (Espace Champerret, 17e arrondissement) tomorrow and on Thursday. Since HCS Pharma was selected as a laureate amongst innovative start-ups and SMEs for this ecent, she will be the first to pitch at 11:40 Read more…
Nanostem
New article published for Nanostem project about the interaction between nanoparticles and the blood-brain barrier in vitro
To treat brain disease is a challeging purpose, since the brain is protected by a barrier made by of tightly-joined endothelial cells of the cerebral microvessels, called the blood–brain barrier (BBB). To improve this route to reach the central nervous system, several strategies have been developed. Among them, researchers try Read more…
News
HCS Pharma will participate in Cosmetic Testing Symposium “Cosmetotest” in Lyon (24th and 25th of May)
We are happy to participate in Cosmetotest, the first Symposium dedicated to preclinical and clinical tests in dermocosmetics the 24th and 25th of May at Lyon. HCS Pharma will be present for the preclinal day, the 24th of May. You could meet Océane (project leader) in this event to discuss about our Read more…
Biomimesys
Poster – A single procedure to generate functional hiPSCs-derived liver organoids -Towards an innovative tool suitable for drug screening
We previously showed that human pluripotent stem cells (hiPSCs) provide a suitable model to study metabolic diseases upon hepatocyte-like cell (HLC) differentiation. In particular, HLCs have been used to model cholesterol metabolism regulation, by mimicking the main disease features in vitro. Human iPSCs can be generated from urine samples of Read more…
News
Save the date for Molecular Devices’ Imaging User Meeting to be held here in Lille (France), May 17-18 !
We are happy to welcome the next Molecular Devices’ Imaging User Meeting here in our laboratories in Lille! We hope it will be maintained in person. For sure it will be a pleasure to participate in the great event, after the last one which took place in Leiden in 2020. Read more…
HCS, HCA & Biology
What is High Content Screening (HCS)?
High Throughput Screening (HTS) has been developed in the 80s, in the context of the automation and miniaturization of techniques for biological assays. Thanks to multiwell plates (96, 384, 1536, or 3456 wells) handled on a platform with robotic arms and automated pipetting systems, it allows to test hundreds of Read more…
Biomimesys
Weldone for successfully completing your PhD, Véronique!
2022 is beginning, but 2021 ended in the most beautiful way… with Véronique De Conto‘s PhD defense. She successfully defended her PhD thesis about the importance of the microenvironment in cerebral in vitro models for phenotypic screening. We had the privilege to maintain the PhD defense on-site, even if one member Read more…
Biomimesys
The extracellular matrix modification in pulmonary fibrosis
The lung is a vital organ which allows gas exchanges between the external environment and the body. These gas exchanges take place in alveoli, formed by 2 cell types : pneumocytes I and II (Martinez et al., 2017). The alveolar wall is supported by a basal membrane mainly composed of collagen Read more…
Application Notes
Increase culture time in BIOMIMESYS® Liver
BIOMIMESYS® Liver recreates the complex cellular microenvironment of the liver to extend longevity and functionality of hepatocytes in culture: The life of human primary hepatocytes grown in a 2D sandwich is low, 3-10 days (1) and is accompanied by dedifferentiation, leading to the loss of their functions. In 2D culture, Read more…
Application Notes
Increased expression of differentiation genes with BIOMIMESYS® Adipose tissue
The morphological changes in cells during differentiation are accompanied by a profound change at the molecular level. In vivo, the adipocyte differentiation process includes early and late events due to differential gene regulation. The appearance of these markers is a sign of differentiation of pre-adipocytes and hence the development of Read more…
Biomimesys
HCS Pharma @ the Joint InnaSCo-FrontInov meeting next week
This year, InnaSCo and Frontinov propose a joint scientific meeting dealing with inflammation, including presentations of prestigious speakers. This meeting will take place next week as a 2-day webinar, on the 20th and 21st October. The first day will be dedicated to quantitative biology approaches for exploration of inflammatory responses. This part of the Read more…
Application Notes
In Vitro-like morphology of adipocytes with BIOMIMESYS® Adipose tissue
Adipocytes have a characteristic round morphology in vivo, due to the production of one large lipid vesicles, created by lipogenesis (1). In conventional cell culture, adipocytes cannot acquire this physiological morphology.
News
3D cell culture, yes… and Made in France!
Want to try 3D cell culture in your lab? Why not testing BIOMIMESYS®, our 3D cell culture system made in France? Please feel free to contact us at hello@biomimesys.com (or with this form) for any question… We will answer in french, or in english 🙂
Biomimesys
Replay of our webinar about BIOMIMESYS Oncology for modelling cancer in 3D
Have you missed our last webinar with Molecular Devices about 3D oncology models? In April, our project leader Elodie was talking about how to establish and image physiologically relevant 3D cancer in vitro models, using BIOMIMESYS Oncology as a surrogate for the tumoral extracellular matrix. Our product BIOMIMESYS® Oncology matrix Read more…
News
Discover our work in Korean, thanks to Molecular Devices
If you want to better known what we are doing now in HCS Pharma and if your native language is korean, you can discover it with this article : HCS Pharma, 생리학적으로 중요한 3d Cell Model의 Phenotypic Screening에 ImageXpress Micro Confocal 시스템 사용 We explain in the text how we Read more…
News
Agrément CIR jusqu’en 2023 pour HCS Pharma
Nous sommes heureux de vous annoncer que le Ministère de l’Enseignement Supérieur et de la Recherche a accordé à HCS Pharma l’agrément au Crédit d’Impôt Recherche (CIR) jusqu’en 2023, en regard de nos activités de R&D. For non-french readers, the CIR (Research Tax Credit) concept is explain here. Our customers can Read more…